ACM
BEAM icon

Aster Capital Management’s Beam Therapeutics BEAM Stock Holding History

Aster Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.7K Buy
+2,954
New +$82K 0.02% 414
2025
Q1 		– Sell
-60
Closed -$1.49K – 1261
2024
Q4 		$1.49K Buy
+60
New +$1.53K ﹤0.01% 992

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Aster Capital Management's BEAM Position: Q1 2026 in Review

Aster Capital Management opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 2,954 shares worth $57.7K. The stake represents 0.02% of the portfolio and ranks #414 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in BEAM as recently as Q4 2024.

Aster Capital Management first reported a position in BEAM in Q4 2024 and has held it in 2 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Aster Capital Management held 2,954 shares of Beam Therapeutics worth $57.7K as of Q1 2026.
  • Beam Therapeutics was a new Aster Capital Management position in Q1 2026.
  • Beam Therapeutics made up 0.02% of Aster Capital Management's portfolio in Q1 2026, its #414 holding.
  • Aster Capital Management first reported a position in Beam Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.